ADAGIO: A Phase IIb, Open-Label, Single-Arm, Multicenter Study Assessing the Efficacy and Safety of Adavosertib (AZD1775) As Treatment for Recurrent or Persistent Uterine Serous Carcinoma.
Journal of clinical oncology official journal of the American Society of Clinical Oncology（2025）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined